For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231122:nRSV1928Ua&default-theme=true
RNS Number : 1928U Cambridge Cognition Holdings PLC 22 November 2023
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Change of Auditor
Cambridge Cognition (AIM: COG), which develops and markets digital solutions
to assess brain health, announces that the Board has approved the appointment
of Crowe UK LLP ("Crowe") as the Group's new external auditor following a
competitive audit tender process, and that Grant Thornton UK LLP ("Grant
Thornton") has resigned as the Group's auditor.
Crowe will conduct the audit of the Group's financial statements for the
financial period to 31 December 2023 and a proposal to re-appoint Crowe as
auditors of the Group will be subject to the approval of shareholders at the
2024 Annual General Meeting.
Grant Thornton has been the auditor for the Company since 2013 and we thank
them for their services over this time. Grant Thornton has confirmed to the
Company that there are no matters connected with their ceasing to hold office
that need to be brought to the attention of the members or creditors of the
Company for the purposes of section 519 of the Companies Act 2006.
Enquiries
Cambridge Cognition Holdings Plc Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com (mailto:press@camcog.com)
Stephen Symonds, Chief Financial Officer
Panmure Gordon (UK) Limited (NOMAD and Joint Broker) Tel: 020 7886 2500
Freddy Crossley / Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END APPBRBDBDBDDGXB